BioAffinity Technologies (BIAF) announced that the Australian Patent Office has accepted a patent application for the company’s proprietary platform technology for assessing lung health and predicting the likelihood of multiple lung diseases in patients. The patent application covers methods that use flow cytometry combined with fluorescent probes, molecular “tags” that attach to specific cell types, to detect cellular and molecular signatures of multiple lung diseases.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIAF:
- bioAffinity Technologies Secures Australian Patent for Lung Health
- bioAffinity Technologies Advances Non-Invasive Lung Cancer Diagnostic Study
- bioAffinity Technologies Advances Lung Cancer Detection with Innovative Study
- bioAffinity Technologies Presents at CHEST 2025 Conference
- bioAffinity Technologies Secures Patent for Lung Cancer Detection